DNA: Daily News & Analysis (India) (03.01.13)
Aids Weekly Plus
India Health Minister Ghulam Nabi Azad said on March 1 that Indian research institutes are conducting trials to test new TB drugs, including drugs to treat currently drug-resistant TB. Drugs the institutes are testing include Delaminid, Bedaquiline, and PA-824, to treat both drug-sensitive and drug-resistant TB. The All India Institute of Medical Sciences, New Delhi, and the National Institute of Research in TB, Chennai, are taking part in global trials for the new TB drug Bedaquiline (TMC207). Azad noted the Drug Controller General of India (DCGI) had not received an application granting permission for a US drug. Per India’s drug and cosmetic rules, DCGI must grant approval for any new drug to be introduced in the Indian market. Azad declared that, currently, the replacement of drugs used under the Revised National Tuberculosis Control Programme was not required, adding that patients with drug-resistant TB are treated with a regimen containing drugs to which the TB bacillus was not resistant.